Frontotemporal dementia - Pipeline Insight, 2021

Frontotemporal dementia - Pipeline Insight, 2021

  • July 2021 •
  • 60 pages •
  • Report ID: 5974302 •
  • Format: PDF
“Frontotemporal dementia - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Frontotemporal dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Frontotemporal dementia Understanding

Frontotemporal dementia: Overview
Frontotemporal dementia (FTD) is a group of related conditions resulting from the progressive degeneration of the temporal and frontal lobes of the brain. These areas of the brain play a significant role in decision-making, behavioral control, emotion and language. The clinical symptoms of FTD are caused by degeneration in the parts of the brain that control decision-making, behavior, emotion and language (typically the frontal, temporal and insular regions). In people under age 60, FTD is the most common cause of dementia and affects as many people as Alzheimer’s disease in the 45–64 age group.

"Frontotemporal dementia - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Frontotemporal dementia pipeline landscape is provided which includes the disease overview and Frontotemporal dementia treatment guidelines. The assessment part of the report embraces, in depth Frontotemporal dementia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Frontotemporal dementia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Frontotemporal dementia R&D. The therapies under development are focused on novel approaches to treat/improve Frontotemporal dementia.

Frontotemporal dementia Emerging Drugs Chapters
This segment of the Frontotemporal dementia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Frontotemporal dementia Emerging Drugs
• PR006: Prevail Therapeutics
PR006 is being developed as a potentially disease-modifying, single-dose gene therapy for patients with frontotemporal dementia with GRN mutations (FTD-GRN). PR006 is designed to slow or stop disease progression in FTD-GRN patients by increasing progranulin levels via delivery of a healthy GRN gene into the central nervous system (CNS). Like PR001, PR006 is administered by injection into the cisterna magna, using the well-studied viral vector AAV9. The U.S. FDA has granted Orphan Drug designation for the treatment of FTD and Fast Track designation for the treatment of FTD-GRN. The European Commission has granted orphan designation for PR006 for the treatment of FTD. PR006 is currently being studied in our PROCLAIM trial, a Phase I/II clinical trial of PR006 for the treatment of patients with FTD-GRN.

• AL001: Alector
AL001, is a humanized recombinant monoclonal antibody that is intended to be delivered by intravenous, peripheral infusion to the bloodstream to increase the levels of PGRN in the brains of FTD-GRN patients. AL001 functions by shutting down the SORT1 degradation mechanism for PGRN and increasing the circulating half-life of the functional PGRN in the brain. AL001 received orphan drug designation from the FDA for the treatment of FTD in 2018. Currently, it is in phase III stage of development to treat Frontotemporal dementia.

Further product details are provided in the report……..

Frontotemporal dementia: Therapeutic Assessment
This segment of the report provides insights about the different Frontotemporal dementia drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Frontotemporal dementia
There are approx. 20+ key companies which are developing the therapies for Frontotemporal dementia. The companies which have their Frontotemporal dementia drug candidates in the most advanced stage, i.e. phase III include, Alector.

• Phases
This report covers around 20+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Frontotemporal dementia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Frontotemporal dementia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Frontotemporal dementia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Frontotemporal dementia drugs.

Frontotemporal dementia Report Insights
• Frontotemporal dementia Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Frontotemporal dementia Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Frontotemporal dementia drugs?
• How many Frontotemporal dementia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Frontotemporal dementia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Frontotemporal dementia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Frontotemporal dementia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Alector
• Prevail Therapeutics
• Passage Bio, Inc.
• TauRx Pharmaceuticals
• Wave Life Sciences Ltd.
• CAMP4 Therapeutics
• Coya Therapeutics
• SOLA Biosciences
• AcuraStem
• Denali Therapeutics
• Wave Life Sciences
• Neurimmune
• Biogen
• Asceneuron SA
• Libra Therapeutics
• Muna Therapeutics
• Alkermes
• Sangamo Therapeutics
• Arkuda Therapeutics
• AZTherapies
• Yumanity
• Autifony Therapeutics
• Prothena

Key Products
• PR006
• AL 001
• PBFT02
• TRx-0237
• WVE-004
• EXO-050
• SOL 257
• AS 201
• AS 202
• DNL593
• NI308
• NI205